Welcome to our dedicated page for Perrigo news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo stock.
Perrigo Company plc reports recurring developments as a pure-play consumer health company focused on over-the-counter self-care products, store-brand private label offerings, and branded health and wellness products primarily in North America and Europe. Company updates cover operating results from continuing operations, category performance, dividends, investor presentations, and portfolio actions under its Three-S plan to stabilize, streamline, and strengthen the business.
News also addresses Perrigo's product-category reporting and brand momentum across Self Care and Specialty Care, including names such as Opill®, Mederma®, Compeed®, EllaOne®, and Jungle Formula®. Recent corporate developments include the completed divestiture of the Dermacosmetics business and the use of portfolio proceeds for balance-sheet debt reduction.
Perrigo (NYSE: PRGO) reported first-quarter 2026 continuing-operations results. Core net sales were $842M, down 8.3% year-over-year (Core organic -11.0%). Reported diluted EPS was $(2.81) driven by a $330.8M goodwill impairment. Core adjusted operating margin was 12.8% and All In adjusted EPS was $0.43.
The company completed the post-quarter sale of its Dermacosmetics business with €305.6M upfront proceeds (up to €332.6M total) to support debt reduction, and reaffirmed full-year 2026 outlook with expected H2 improvement.
Perrigo (NYSE: PRGO) completed the sale of its branded Dermacosmetics business to Karo Healthcare for up to €332.6 million, consisting of €305.6 million upfront (including €5.6 million net working capital adjustment) and up to €27.0 million contingent over three years. Brands sold include ACO, Biodermal, Emolium, and Iwostin. Perrigo reported the divested unit had ~€120 million in 2025 net sales and represented ~5% of adjusted operating income. Perrigo said net proceeds will be used primarily to reduce debt and strengthen the balance sheet.
Perrigo (NYSE: PRGO) announced a quarterly cash dividend of $0.29 per share, equal to $1.16 annually. The dividend is payable on June 16, 2026 to shareholders of record on May 29, 2026. The release reiterates Perrigo's consumer health focus and investor relations contacts.
Perrigo (NYSE: PRGO) will release first quarter 2026 financial results on May 6, 2026 and host an earnings conference call at 8:30 A.M. ET. The call will stream live via the investor relations webcast and is accessible by phone; a taped replay will be available through May 13, 2026.
Investor contacts and replay/access details are provided for shareholders and analysts.
Perrigo (NYSE: PRGO) announced that President and CEO Patrick Lockwood-Taylor will present at the UBS Global Consumer and Retail Conference on Wednesday, March 11, 2026 at 11:00 AM EDT. A live webcast will be available on Perrigo's investor website.
The presentation will cover the company’s consumer health strategy and recent developments; investors can access slides and a replay via the Perrigo investor page.
Perrigo (NYSE: PRGO) reported Q4 2025 net sales of $1.11B (-2.5%) and FY2025 net sales of $4.25B (-2.8%). The company recorded a $1.3B goodwill impairment in Q4 and delivered FY2025 adjusted EPS of $2.75 (up 7%). Cash was $532M at 12/31/25.
Perrigo announced FY2026 outlook: All In adjusted EPS $2.00–$2.30 and net sales -5.5% to -1.5; CORE adjusted EPS $2.25–$2.55 and CORE net sales -3.0% to +1.0. Project Energize and Supply Chain programs delivered material savings.
Perrigo (NYSE: PRGO) announced a quarterly cash dividend of $0.29 per share, equal to $1.16 annualized. The dividend is payable on March 24, 2026 to shareholders of record as of March 2, 2026.
The release reiterates Perrigo's consumer health focus and includes standard forward-looking statement language.
Perrigo (NYSE: PRGO) said it will release fourth quarter and fiscal year 2025 results on February 26, 2026 and host an earnings call at 8:30 A.M. ET. The call will be live via webcast and available by phone; a taped replay is provided through March 5, 2026.
Perrigo is a consumer health company with leading OTC brands and directs investors to its SEC filings for risks and additional details.
Perrigo (NYSE: PRGO) reported third-quarter 2025 results on Nov. 5, 2025 showing Q3 net sales of $1.04 billion (down 4.1% YoY) and adjusted operating income of $173 million. Q3 adjusted EPS was $0.80 (vs. $0.81 prior year). Year-to-date 2025 adjusted EPS rose to $1.97 (+20.9% reported; +27.0% organically) and adjusted operating income was $455 million (+9.8%). The company achieved store-brand share gains in 5 of 7 OTC categories and six consecutive months of store-brand volume share gains. Perrigo initiated a strategic review of its Infant Formula business, continues a review of Oral Care, and expects to close the Dermacosmetics sale in Q1 2026. Fiscal 2025 outlook updated to net sales -2.5% to -3.0% and adjusted EPS $2.70–$2.80 reflecting industry dynamics and soft OTC consumption.
Perrigo (NYSE: PRGO) announced on November 5, 2025 that it is initiating a strategic review of its infant formula business to assess a full range of alternatives aligned with its Three-S plan (Stabilize, Streamline, Strengthen).
The review will reconsider a prior $240 million investment and focus on accelerating cash flows and optimizing portfolio impact. The infant formula business is expected to generate ~$360 million in 2025, ~90% of Perrigo's Nutrition category and under 10% of Perrigo's annual net sales. No decisions or timetable have been set; Perrigo will continue supplying product during the review.